A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/7004 (2006.01) A61K 31/155 (2006.01) A61K 31/445 (2006.01) A61K 31/64 (2006.01) A61K 31/7048 (2006.01) A61K 31/706 (2006.01) A61P 3/00 (2006.01) A61P 3/10 (2006.01)
Patent
CA 2669043
The present invention is directed to a pharmaceutical composition comprised of one or more SGLT-2 inhibitor compound(s) in combination with one or more therapeutic agents which is suitable for the treatment of metabolic disorders including type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, hyperglycemia, postprandial hyperglycemia, overweight, obesity, including class I obesity, class II obesity, class III obesity, visceral obesity and abdominal obesity, and metabolic syndrome.
L'invention concerne une composition pharmaceutique comprenant un ou plusieurs composés inhibiteurs de SGLT-2 combinés avec un ou plusieurs agents thérapeutiques. Cette composition pharmaceutique est appropriée dans le traitement des troubles métaboliques comprenant le diabète insulinodépendant, le diabète non insulinodépendant, une altération de la tolérance au glucose, l'hyperglycémie, l'hyperglycémie postprandiale, le surpoids, l'obésité, y compris l'obésité de classe I, l'obésité de classe II, l'obésité de classe III, l'obésité viscérale et l'obésité abdominale, et le syndrome métabolique.
Dugi Klaus
Eickelmann Peter
Manuchehri Alireza
Thomas Leo
Boehringer Ingelheim International Gmbh
Fetherstonhaugh & Co.
LandOfFree
Combination therapy with sglt-2 inhibitors and their... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combination therapy with sglt-2 inhibitors and their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapy with sglt-2 inhibitors and their... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1726531